Effect of genetic polymorphisms on the pharmacokinetics and efficacy of glimepiride in a Korean population

Clinica Chimica Acta

Volumn 412, Issue 19-20, 2011, Pages 1831-1834

  Cho, Hyun Jung ^a   Lee, Soo Youn ^b,d   Kim, Youn Gyoon ^c   Oh, Soo Yeon ^c   Kim, Jong Won ^b   Huh, Woo Seong ^b,d   Ko, Jae Wook ^d   Kim, Hyung Gun ^c  

^a Konyang University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Dankook University   (South Korea)

^d Samsung Medical Center   (South Korea)

Author keywords

Diabetes; Glimepiride; Korean subjects; SNP

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C8; CELL PROTEIN; CYTOCHROME P450 2C9; GENOMIC DNA; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; PROTEIN NOS1AP; TRANSCRIPTION FACTOR 7 LIKE 2; UNCLASSIFIED DRUG;

ABCC8 GENE; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYP2C9 GENE; DNA SEQUENCE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; KCNJ11 GENE; MALE; MAXIMUM PLASMA CONCENTRATION; MUTATION RATE; NORMAL HUMAN; NOS1AP GENE; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH KOREA; TCF7L2 GENE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; BLOOD GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KOREA; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; SULFONYLUREA COMPOUNDS;

EID: 79960640087     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.06.014     Document Type: Article

References (54)

1. Zimmet P., Alberti K.G., Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787.
2. IDF Diabetes and obesity: urgent action needed 2004.
3. Langtry H.D., Balfour J.A. Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Drugs 1998, 55:563-584.
4. Kramer W., Muller G., Geisen K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells. Horm Metab Res 1996, 28:464-468.
5. Schneider J. An overview of the safety and tolerance of glimepiride. Horm Metab Res 1996, 28:413-418.
6. Massi-Benedetti M. Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience. Clin Ther 2003, 25:799-816.
7. Rosenstock J., Samols E., Muchmore D.B., Schneider J. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. Diabetes Care 1996, 19:1194-1199.
8. Muller G., Hartz D., Punter J., Okonomopulos R., Kramer W. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics. Biochim Biophys Acta 1994, 1191:267-277.
9. Kabadi M.U., Kabadi U.M. Effects of glimepiride on insulin secretion and sensitivity in patients with recently diagnosed type 2 diabetes mellitus. Clin Ther 2004, 26:63-69.
10. Blaum C.S., Velez L., Hiss R.G., Halter J.B. Characteristics related to poor glycemic control in NIDDM patients in community practice. Diabetes Care 1997, 20:7-11.
11. Hermann L.S., Schersten B., Bitzen P.O., Kjellstrom T., Lindgarde F., Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994, 17:1100-1109.
12. Gloyn A.L., Hashim Y., Ashcroft S.J., Ashfield R., Wiltshire S., Turner R.C. Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53). Diabet Med 2001, 18:206-212.
13. Hansen T., Echwald S.M., Hansen L., et al. Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene. Diabetes 1998, 47:598-605.
14. Pearson E.R., Donnelly L.A., Kimber C., et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 2007, 56:2178-2182.
15. Pearson E.R., Donnelly L.A., Kimber C., et al. Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea. Pharmacogenet Genomics 2008, 18:591-597.
16. Willer C.J., Bonnycastle L.L., Conneely K.N., et al. Screening of 134 single nucleotide polymorphisms (SNPs) previously associated with type 2 diabetes replicates association with 12 SNPs in nine genes. Diabetes 2007, 56:256-264.
17. Ren Q., Han X.Y., Wang F., et al. Exon sequencing and association analysis of polymorphisms in TCF7L2 with type 2 diabetes in a Chinese population. Diabetologia 2008, 51:1146-1152.
18. Grant S.F., Thorleifsson G., Reynisdottir I., et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006, 38:320-323.
19. Luo Y., Wang H., Han X., et al. Meta-analysis of the association between SNPs in TCF7L2 and type 2 diabetes in East Asian population. Diabetes Res Clin Pract 2009, 85:139-146.
20. Miyake K., Horikawa Y., Hara K., et al. Association of TCF7L2 polymorphisms with susceptibility to type 2 diabetes in 4,087 Japanese subjects. J Hum Genet 2008, 53:174-180.
21. Badian M., Korn A., Lehr K.H., Malerczyk V., Waldhausl W. Pharmacokinetics and pharmacodynamics of the hydroxymetabolite of glimepiride (Amaryl) after intravenous administration. Drug Metabol Drug Interact 1996, 13:69-85.
22. Yun H.Y., Park H.C., Kang W., Kwon K.I. Pharmacokinetic and pharmacodynamic modelling of the effects of glimepiride on insulin secretion and glucose lowering in healthy humans. J Clin Pharm Ther 2006, 31:469-476.
23. Cauchi S., Meyre D., Dina C., et al. Transcription factor TCF7L2 genetic study in the French population: expression in human beta-cells and adipose tissue and strong association with type 2 diabetes. Diabetes 2006, 55:2903-2908.
24. Florez J.C., Jablonski K.A., Bayley N., et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. NEJM 2006, 355:241-250.
25. Melzer D., Murray A., Hurst A.J., et al. Effects of the diabetes linked TCF7L2 polymorphism in a representative older population. BMC Med 2006, 4:34.
26. Saxena R., Gianniny L., Burtt N.P., et al. Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes 2006, 55:2890-2895.
27. Kirchhoff K., Machicao F., Haupt A., et al. Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion. Diabetologia 2008, 51:597-601.
28. Gonzalez-Sanchez J.L., Martinez-Larrad M.T., Zabena C., Perez-Barba M., Serrano-Rios M. Association of variants of the TCF7L2 gene with increases in the risk of type 2 diabetes and the proinsulin:insulin ratio in the Spanish population. Diabetologia 2008, 51:1993-1997.
29. Dahlgren A., Zethelius B., Jensevik K., Syvanen A.C., Berne C. Variants of the TCF7L2 gene are associated with beta cell dysfunction and confer an increased risk of type 2 diabetes mellitus in the ULSAM cohort of Swedish elderly men. Diabetologia 2007, 50:1852-1857.
30. Loos R.J., Franks P.W., Francis R.W., et al. TCF7L2 polymorphisms modulate proinsulin levels and beta-cell function in a British Europid population. Diabetes 2007, 56:1943-1947.
31. Stolerman E.S., Manning A.K., McAteer J.B., et al. TCF7L2 variants are associated with increased proinsulin/insulin ratios but not obesity traits in the Framingham Heart Study. Diabetologia 2007, 52:614-620.
32. Yi F., Brubaker P.L., Jin T. TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem 2005, 280:1457-1464.
33. Deacon C.F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 2004, 53:2181-2189.
34. Damcott C.M., Pollin T.I., Reinhart L.J., et al. Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in the Amish: replication and evidence for a role in both insulin secretion and insulin resistance. Diabetes 2006, 55:2654-2659.
35. Lehman D.M., Hunt K.J., Leach R.J., et al. Haplotypes of transcription factor 7-like 2 (TCF7L2) gene and its upstream region are associated with type 2 diabetes and age of onset in Mexican Americans. Diabetes 2007, 56:389-393.
36. Chandak G.R., Janipalli C.S., Bhaskar S., et al. Common variants in the TCF7L2 gene are strongly associated with type 2 diabetes mellitus in the Indian population. Diabetologia 2007, 50:63-67.
37. Horikoshi M., Hara K., Ito C., Nagai R., Froguel P., Kadowaki T. A genetic variation of the transcription factor 7-like 2 gene is associated with risk of type 2 diabetes in the Japanese population. Diabetologia 2007, 50:747-751.
38. Hayashi T., Iwamoto Y., Kaku K., Hirose H., Maeda S. Replication study for the association of TCF7L2 with susceptibility to type 2 diabetes in a Japanese population. Diabetologia 2007, 50:980-984.
39. Humphries S.E., Gable D., Cooper J.A., et al. Common variants in the TCF7L2 gene and predisposition to type 2 diabetes in UK European Whites, Indian Asians and Afro-Caribbean men and women. J Mol Med 2006, 84:1005-1014.
40. van Vliet-Ostaptchouk J.V., Shiri-Sverdlov R., Zhernakova A., et al. Association of variants of transcription factor 7-like 2 (TCF7L2) with susceptibility to type 2 diabetes in the Dutch Breda cohort. Diabetologia 2007, 50:59-62.
41. Scott L.J., Bonnycastle L.L., Willer C.J., et al. Association of transcription factor 7-like 2 (TCF7L2) variants with type 2 diabetes in a Finnish sample. Diabetes 2006, 55:2649-2653.
42. Sladek R., Rocheleau G., Rung J., et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007, 445:881-885.
43. Schulz R., Rassaf T., Massion P.B., Kelm M., Balligand J.L. Recent advances in the understanding of the role of nitric oxide in cardiovascular homeostasis. Pharmacol Ther 2005, 108:225-256.
44. Massion P.B., Pelat M., Belge C., Balligand J.L. Regulation of the mammalian heart function by nitric oxide. Comp Biochem Physiol A Mol Integr Physiol 2005, 142:144-150.
45. Lajoix A.D., Reggio H., Chardes T., et al. A neuronal isoform of nitric oxide synthase expressed in pancreatic beta-cells controls insulin secretion. Diabetes 2001, 50:1311-1323.
46. Gunawardana S.C., Rocheleau J.V., Head W.S., Piston D.W. Mechanisms of time-dependent potentiation of insulin release: involvement of nitric oxide synthase. Diabetes 2006, 55:1029-1033.
47. Aguilar-Bryan L., Bryan J. Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocr Rev 1999, 20:101-135.
48. Florez J.C., Burtt N., de Bakker P.I., et al. Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes 2004, 53:1360-1368.
49. Hamming K.S., Soliman D., Matemisz L.C., et al. Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel. Diabetes 2009, 58:2419-2424.
50. Shikata E., Yamamoto R., Takane H., et al. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet 2007, 52:117-122.
51. Shu Y., Sheardown S.A., Brown C., et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007, 117:1422-1431.
52. Pearson E.R., Liddell W.G., Shepherd M., Corrall R.J., Hattersley A.T. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes. Diabet Med 2000, 17:543-545.
53. Sesti G., Laratta E., Cardellini M., et al. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metab 2006, 91:2334-2339.
54. Feng Y., Mao G., Ren X., et al. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diabetes Care 2008, 31:1939-1944.